Friedman briefed journalists in September 2021: Governments Spur Rare Disease Treatments.

Aaron Friedman is a Senior Regulatory Counsel in the FDA’s Office of Orphan Products Development. He has worked in OOPD since 2016 on legal and policy matters related to the Orphan Drug Designation Program, the Rare Pediatric Disease Priority Review Voucher Program and OOPD’s grants programs. Much of Friedman’s work has focused on orphan drug exclusivity issues, including complex exclusivity matters involved in litigation and citizen petitions. Prior to joining OOPD, he worked in the FDA’s Office of Regulatory Affairs and the Center for Tobacco Products. Friedman received his BA from the University of Virginia and JD from the University of Virginia School of Law.